Search

Your search keyword '"Michael Chiarella"' showing total 8 results
Start Over Author "Michael Chiarella" Publisher elsevier bv
8 results on '"Michael Chiarella"'

1. Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Author

Robert J. Ryan, Michael Chiarella, and Jorge E. Cortes

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Myeloid leukemia, Hematology, Newly diagnosed, Internal medicine, Relapsed refractory, Medicine, Conventional chemotherapy, Clinical safety, In patient, business
Published
2019
Full Text
View/download PDF

2. Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study

Author

Michael Chiarella, Gary J. Schiller, Stefan Faderl, Ellen K. Ritchie, Robert J. Ryan, and Jorge E. Cortes

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Secondary Acute Myeloid Leukemia, Phases of clinical research, Hematology, Exploratory analysis, Newly diagnosed, business
Published
2019
Full Text
View/download PDF

3. Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin

Author

Donna E. Hogge, Stephen A. Strickland, Geoffrey L. Uy, Arthur C. Louie, Jorge E. Cortes, Jeffrey E. Lancet, Jonathan E. Kolitz, Stuart L. Goldberg, Michael Chiarella, and Robert J. Ryan

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Daunorubicin, Phases of clinical research, Hematology, Newly diagnosed, 03 medical and health sciences, 0302 clinical medicine, Older patients, 030220 oncology & carcinogenesis, Internal medicine, medicine, Cytarabine, Secondary Acute Myeloid Leukemia, business, 030217 neurology & neurosurgery, medicine.drug
Published
2018
Full Text
View/download PDF

4. Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Author

Richard Stone, Scott R. Solomon, Ellen K. Ritchie, Jeffrey E. Lancet, Arthur C. Louie, Dale L. Bixby, Matthew J. Wieduwilt, Donna E. Hogge, Laura F. Newell, Bruno C. Medeiros, Geoffrey L. Uy, Daniel H. Ryan, Michael Chiarella, Jonathan E. Kolitz, Robert K. Stuart, Tara L. Lin, Stephen A. Strickland, Antje Hoering, Jorge E. Cortes, and Gary J. Schiller

Subjects
Oncology, Transplantation, medicine.medical_specialty, Liposome, business.industry, Daunorubicin, Hematology, Treatment efficacy, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Immunology, Cytarabine, Medicine, Secondary Acute Myeloid Leukemia, business, 030215 immunology, medicine.drug
Published
2017
Full Text
View/download PDF

5. Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)

Author

Stephen A. Strickland, Michael Chiarella, Dale L. Bixby, Arthur C. Louie, Laura F. Newell, Robert J. Ryan, Bruno C. Medeiros, Nikolai A. Podoltsev, Bayard L. Powell, Donna E. Hogge, Tara L. Lin, Jeffrey E. Lancet, Harry P. Erba, and Scott D. Solomon

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Myeloid leukemia, Subgroup analysis, Hematology, Newly diagnosed, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Flt3 mutation, medicine, Overall survival, In patient, Stem cell, Intensive care medicine, business, 030217 neurology & neurosurgery
Published
2017
Full Text
View/download PDF

6. Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study

Author

Harry P. Erba, Michael Chiarella, Robert J. Ryan, Scott D. Solomon, Geoffrey L. Uy, Arthur C. Louie, Robert K. Stuart, Jonathan E. Kolitz, David A. Rizzieri, Jorge E. Cortes, Gary J. Schiller, Laura F. Newell, and Jeffrey E. Lancet

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Phases of clinical research, Subgroup analysis, Hematology, Newly diagnosed, Therapy-Related Acute Myeloid Leukemia, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, business, 030217 neurology & neurosurgery
Published
2017
Full Text
View/download PDF

7. Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML)

Author

Robert J. Ryan, Arthur C. Louie, Robert K. Stuart, Michael Chiarella, Jorge E. Cortes, Stephen A. Strickland, Jonathan E. Kolitz, Donna E. Hogge, Jeffrey E. Lancet, Bruno C. Medeiros, Karen Chung, and Stuart L. Goldberg

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Internal medicine, Overall survival, Myeloid leukemia, Phases of clinical research, Medicine, Hematology, Newly diagnosed, business, Intensive care medicine
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results